0
Editorials |

Rebuttal From Dr LightRebuttal From Dr Light

Richard W. Light, MD
Author and Funding Information

From the Division of Allergy, Pulmonary, Immunology and Critical Care, Vanderbilt University.

Correspondence to: Richard W. Light, MD, FCCP, Vanderbilt University, 2201 W End Ave, Nashville, TN 37235; e-mail: rlight98@yahoo.com

Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Light has been on the advisory board of and is a consultant to CareFusion, which makes the Pleurx indwelling catheter, and CareFusion has provided support for some of his speaking engagements.


Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Light has been on the advisory board of and is a consultant to CareFusion, which makes the Pleurx indwelling catheter, and CareFusion has provided support for some of his speaking engagements.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2012;142(1):20-21. doi:10.1378/chest.12-1088
Text Size: A A A
Published online

Extract

Patients with a malignant effusion have a mean life expectancy of only several months. It is, therefore, incumbent upon physicians caring for these patients to manage their effusions in a manner that will provide them the most high-quality days during the remainder of their lives.

Dr Lee’s1 conclusion that the optimal treatment of pleural effusion is thoracoscopic talc pleurodesis appears to be based on two reviews, which were both published in 2006 and concluded that talc was the sclerosant of choice and that thoracoscopy was the preferred technique. Neither of these reviews included the article by Dresler et al,2 which showed that overall there was no difference in the percentage of successful pleurodesis whether the patient received talc via tube thoracostomy or via thoracoscopy. Lee goes on to note that in the study reported by Dresler et al,2 the pleurodesis was more successful in patients with breast and lung carcinoma subjected to thoracostomy. This means that the patients with other malignancies who received thoracoscopy did worse. This study was not originally designed for subset analysis, so one must be careful of making conclusions from subset analysis. As Davies et al3 point out, all randomized trials to date have failed to show a benefit of thoracoscopic talc poudrage over bedside chemical pleurodesis in the treatment of malignant pleural effusion.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543